Objective: Proinflammatory cytokines are associated with bipolar disorder (BD), but less is known about how cytokines function during the interepisode period. This study examined cytokines, mood symptoms, and sleep in individuals with interepisode BD with complaints of insomnia. We also investigated the effects of a BD-specific modification of cognitive behavior therapy for insomnia (CBTI-BP) on cytokine levels. Methods: Twenty-two adults with interepisode BD type I and insomnia were drawn from a subset of a National Institute of Mental Health funded study. Participants were randomly allocated to CBTI-BP (n = 11) or psychoeducation (n = 11). Participants completed a sleep diary, rated self-report measures of mania and depression, and provided samples assayed for interleukin (IL)-6 and tumor necrosis factor soluble receptor 2 (sTNF-R2).
B
ipolar disorder (BD) affects nearly 4% of the population and is among the top 10 leading causes of disability (1, 2) . Mania symptoms, depression symptoms, and sleep disturbance are hallmark features of BD (3) (4) (5) . Although extant research has identified a range of cognitive, behavioral, social, and clinical predictors of core aspects of BD, the biological correlates are not well defined.
There is evidence implicating inflammation as one putative biological mechanism across psychiatric conditions. Peripheral levels of proinflammatory cytokines-proteins that coordinate adaptive and innate immune response-are a common measure of systemic inflammation. Altered proinflammatory cytokines have been observed in major depressive disorder (6) (7) (8) , schizophrenia (9) , and anxiety disorders (10, 11) . In addition, proinflammatory cytokines have been linked to poor physical health outcomes (6) , neuropsychological impairment (12) , and chronic pain (13) ; outcomes occur at elevated rates in psychiatric conditions. Goldstein et al. (14) have proposed that inflammation may also be an important biological mechanism in BD. Their model first describes bidirectional relationships between mania or depression and inflammation. Next, these paths are mediated by sleep disturbance or chronic pain. The resulting inflammation then leads to negative mental and physical health consequences. Episodes of mania and bipolar depression have generally been associated with increased proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-related molecules (e.g., TNF-α, soluble TNF receptor 1 [sTNF-R1], and soluble TNF receptor 2 [sTNF-R2] (15) (16) (17) (18) (19) (20) (21) ). Previous research has also suggested that the increase in proinflammatory cytokines associated with mania and depression may be resolved during the interepisode period (15, (22) (23) (24) . However, more work is needed to determine whether subsyndromal symptoms of mania and depression may be associated with elevated proinflammatory cytokines during the interepisode period.
Subsyndromal symptoms during the interepisode period are common and associated with relapse to episodes of mania and depression (3, 25, 26) . Examining the relationship between subsyndromal mood symptoms and proinflammatory cytokines may be useful for understanding impairment during the interepisode period. Evidence for the relationship between proinflammatory cytokines and symptom measures of mania and depression has been inconsistent or nonsignificant during acute mood episodes (15, 17, 18, (27) (28) (29) (30) (31) . However, the relationship between mood symptoms and proinflammatory cytokines has not been considered during the interepisode period. Nor has there been work examining the pathway between sleep disturbance and proinflammatory cytokines in BD.
Sleep disturbance such as short sleep duration and insomnia has been strongly implicated in BD (3, 25, 32, 33) . Shorter sleep duration has been connected to increased IL-6 activity in other clinical samples (34, 35) , adolescents (36) , and older men (37) . However, a meta-analysis suggests that these effects may be small (38) . Furthermore, the effect of sleep deprivation on TNF-α, sTNF-R1, and sTNF-R2 activity is mixed (39) (40) (41) (42) (43) . Chronic insomnia is related to increased IL-6 as well as a shift from nighttime to daytime IL-6 and TNF-α secretion (34, 44) . Total wake time (TWT) during the night, which reflects the sleep disturbance characteristic of insomnia (45) , is also positively associated with IL-6 in chronic insomnia (34) . Furthermore, cytokines may have a reciprocal influence on sleep disturbance, which is supported by a study that reported that higher TNF levels before sleep were associated with greater sleep continuity whereas lower sleep continuity was related to higher TNF production in the morning among adults with rheumatoid arthritis (46) . Although these studies suggest that proinflammatory markers may be related to sleep disturbance in the general population and other disorders, to the best of our knowledge, no studies have examined this relationship in BD. Notably, however, it has been hypothesized that IL-6 is related to sleep disturbance in BD (14, 47) . Similarly, TNF-related molecules such as TNF-α, sTNF-R1, and sTNF-R2 may also be implicated given evidence for elevated activity during episodes of mania and depression as well as some evidence that sleep disturbance may be related to TNF activity (16) (17) (18) (19) (20) (21) 35, 38, 39, (41) (42) (43) .
The aim of this study was to examine inflammation in interepisode BD by empirically evaluating components of the Goldstein et al. (14) model of inflammation in BD. This study also tested whether targeting a component of this model-sleep disturbance-can result in changes in measures of inflammation. The first aim was to test the relationship between mood symptoms and proinflammatory cytokines in participants with interepisode bipolar I disorder and insomnia. It was hypothesized that mania and depression symptoms would be positively associated with IL-6 and sTNF-R2. The second aim was to test the relationship between sleep disturbance and proinflammatory cytokines in BD. It was hypothesized that total sleep time (TST) would be negatively associated with IL-6 and sTNF-R2 and TWT would be positively associated with IL-6 and sTNF-R2. The third aim was to test whether a BD-specific modification of cognitive behavior therapy for insomnia (CBTI-BP) can affect proinflammatory cytokines in patients with interepisode bipolar I disorder and insomnia. It was hypothesized that CBTI-BP compared with psychoeducation (PE) would be associated with decreased IL-6 and sTNF-R2 from pretreatment to posttreatment.
METHOD Participants
The participants for the current study were drawn from a subset of those enrolled in a National Institute of Mental Health pilot randomized controlled trial (RCT) to determine whether CBTI-BP can improve mood state, sleep, and functioning (48) . Data were collected from April 2011 to March 2012. Oral mucosal transudate (OMT) collection was added to collect pilot data on inflammatory markers after 29 of the total 58 participants were enrolled, providing a sample of 29 participants for OMT collection. Two participants did not consent to OMT collection and five participants had samples that were unable to be assayed, providing a total sample of 22 participants with OMT for analysis. There were no significant differences on demographic or clinical characteristics between participants with OMT data (n = 22) compared with participants without OMT data (n = 36). Participants that provided OMT samples had significantly longer TWT (t(54) = 2.30, p = .026). There were no other significant differences for any sleep variables between participants that did or did not provide OMT samples. Twenty-two adults with interepisode bipolar I disorder and insomnia received CBTI-BP (n = 11) or PE (n = 11). Among the randomized participants in the present sample, three CBTI-BP participants and two PE participants dropped out during treatment. Attrition rates were not significantly different between treatment groups in the present sample (χ 2 (1, n = 22) = 0.26, p = .61). Demographic characteristics of the present sample are presented in Table 1 . Detailed information on study design and inclusion/exclusion criteria can be found elsewhere (see the study by Harvey et al. (48) ). All study procedures were approved by the University of California, Berkeley, Institutional Review Board. Informed consent was obtained for all participants.
Treatments

Bipolar Disorder-Specific Modification of Cognitive Behavior Therapy for Insomnia (CBTI-BP)
Cognitive behavioral therapy for insomnia was modified to increased safety and tolerability related to stimulus control and sleep restriction (48) . To minimize the risk of hypomania or mania relapse resulting from sleep deprivation, time in bed was restricted to no less than 6.5 hours. Cognitive behavioral therapy for insomnia was also modified to target features of sleep in BD by incorporating components of interpersonal and social rhythm therapy, chronotherapy, and motivational interviewing. The first session focused on case formulation, goal setting, motivational interviewing, and sleep/circadian education. Subsequent sessions included behavioral modules (e.g., stimulus control, sleep restriction, and regularizing sleep-wake times) and cognitive modules (e.g., correcting unhelpful sleep-related beliefs and reducing sleep-related worry or vigilance).
Duke Structured Interview for Sleep Disorders
The Duke Structured Interview for Sleep Disorders is a semistructured interview that assesses sleep disorders defined by DSM-IV and International Classification of Sleep Disorders-2 criteria (50). The Duke Structured Interview for Sleep Disorders was used to assess diagnostic criteria for primary insomnia.
Young Mania Rating Scale
The Young Mania Rating Scale (YMRS) is an 11-item measure rated on a five-point scale used to assess mania symptoms. It has been shown to have good reliability and validity (51) . The YMRS was also examined with the sleep items (item #1) removed.
Quick Inventory of Depressive Symptomatology
The Quick Inventory of Depressive Symptomatology (QIDS) is a 16-item measure rated on a four-point scale used to assess depression symptoms (52) . The measure has demonstrated good reliability and validity (52) . The QIDS was also examined with the sleep items (items #1-4) removed.
Sleep Diary
The sleep diary was based on the Expanded Consensus Sleep Diary for Morning, a validated self-report measure of sleep patterns (53, 54) . Sleep diary was recorded each morning for 1 week preceding the laboratory assessment. In the present study, TST and TWT were the primary measures of sleep disturbance. TST was selected because shortened TST is linked to increased mania symptoms (33) , depression symptoms (32), and proinflammatory cytokines (34, 55, 56) . TWT was selected because it reflects the core insomnia diagnostic criteria (45) , is associated with negative mood in BD (25) , and is related to proinflammatory cytokines in insomnia (34) . TWT was calculated as a composite of sleep onset latency, wake after sleep onset, and early morning awakening (25) .
Collection and Measurement of Cytokines
OMT samples were collected with OraSure devices (OraSure Technologies, Bethlehem, PA). OMT has been validated for assessing proinflammatory cytokines and is correlated with levels found in plasma (57) . Samples were collected 1 week before and after the 8-week treatment. All samples were collected between 3:00 and 7:00 PM. (58) . The OraSure device contains a cotton fiber pad treated with a hypertonic salt solution that enhances the transport of OMT across the gingival crevice and oral mucosa (59, 60) . The cotton pad is held between the right lower cheek and gum for 3 minutes. The cotton pad is then inserted into a tube containing a buffer solution to preserve the sample. After collection, oral fluids were centrifuged at 800 g for 15 minutes and then stored at −80°C until processed. All biochemical analyses were conducted by ProNovus Bioscience, LLC (Mountain View, CA). All biochemical assays were conducted with IL-6 and sTNF-R2 Quantikine ELISA kits (R&D Systems, Minneapolis, MN). sTNF-R2 is the soluble receptor for TNF, which reflects TNF activity and is more stable than measuring TNF directly (61, 62) . Assay sensitivities were 0.11 and 2.3 pg/ml for IL-6 and sTNF-RII, respectively. Minimum detectable dose was 0.01 and 1.4 pg/ml for IL-6 and sTNF-RII, respectively. Intra-and interassay coefficients of variation for the IL-6 ELISA were 3.6% and 5.2%, respectively. Intra-and interassay coefficients of variation for the sTNF-RII ELISA were 0.6% and 1.02%, respectively. Sensitivity and reliability values were provided by ProNovus Bioscience, LLC (Mountain View). All assay kits were validated and all samples were assayed on the same lot. Each sample was tested in duplicate. The Shapiro-Wilk normality test indicated that unadjusted IL-6 (W = .64, p < .001) and sTNF-R2 (W = .73, p < .001) values were not normally distributed. Hence, values were log transformed, which resulted in values that fit a normal distribution for IL-6 (W = .95, p = .270) and sTNF-R2 (W = .95, p = .312). Histograms for unadjusted and log-transformed values for IL-6 and sTNF-R2 are displayed in Figure S1 , Supplemental Digital Content 1, http://links.lww. com/PSYMED/A419.
Medications
A pharmacotherapy tracking log was completed at pretreatment and posttreatment. Dose, time of day taken, frequency of use, missed doses, and adverse effects were assessed. 21 participants (95.5%) were prescribed mood stabilizers and 12 participants (54.5%) were prescribed sleep medication.
Data Analysis
The first two aims were addressed with nonparametric Spearman correlations. The third aim used hierarchical linear models with restricted maximum likelihood estimation. This statistical method can account for the relationships between repeated measurements and does not have the same missing data restrictions of traditional regression analyses. The fixed part of the model included an indicator for treatment condition (CBTI-BP and PE), time (pretreatment and posttreatment) and the interaction between treatment condition and time. The random part of the model included a random intercept for participant.
This study was a pilot study and thus was not powered to obtain statistically significant effects at the .05 level (63, 64) . Reporting and interpreting results will emphasize effect sizes in addition to statistical significance (65) . The correlation coefficient is a measure of effect size and will be interpreted as 0.10 having a small effect size, 0.30 having a medium effect size, and 0.50 having a large effect size (66, 67) . The treatment effect on the change in proinflammatory cytokines from pretreatment to posttreatment was expressed as Cohen's d and will be interpreted as 0.20 having small effect size, 0.50 having medium effect size, and 0.80 having large effect size (66) . Given that this was a pilot study with a small sample size, covariates CBTI-BP = cognitive behavior therapy for insomnia modified for bipolar disorder; PE = psychoeducation; M = mean; SD = standard deviation; IL-6 = interleukin 6; sTNF-R2 = tumor necrosis factor soluble receptor 2; YMRS = Young Mania Rating Scale; QIDS = Quick Inventory of Depressive Symptomatology; TST = total sleep time; TWT = total wake time; WASO = wake after sleep onset.
The t statistic and p value refer to the interaction between condition (CBTI-BP and PE) and time (pretreatment and posttreatment). a Log transformed.
b Unadjusted.
c Sleep items removed.
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were not included to reduce the possibility of overfitting models (68) . All statistical analyses were conducted with R (69).
RESULTS
Means, SDs, and intercorrelations for study variables are presented in Tables 1 to 3 There was a nonsignificant, small-medium effect size difference in sTNF-R2 at pretreatment for CBTI-BP compared with PE (B = 0.29, SE = 0.45, z = 0.64, p = .52, d = 0.31). Change in sTNF-R2 from pretreatment to posttreatment for CBTI-BP compared with PE was associated with a nonsignificant, 
DISCUSSION
The present study aimed to provide a preliminary test for sleeprelated predictions derived from the Goldstein et al. (14) conceptual model of inflammation in BD. At the outset, we recognize that the present study was underpowered. As such, interpretation of results will include a focus on effect sizes in addition to statistical significance at the .05 level (65) . Our first hypothesis was partially supported. IL-6 was positively correlated with mania and depression symptoms, both with and without the sleep items included. However, sTNF-R2 was associated with symptom measures of mood with small effect sizes. These results are consistent with previous research that has demonstrated that IL-6 is elevated during mania and depressive episodes (15, 16, 18) . The present study provides preliminary evidence that even during the interepisode period, IL-6 may be related to subsyndromal mania and depression symptoms with mediumlarge effect sizes. This is noteworthy because previous research has suggested that the increase in proinflammatory cytokines associated with mania and depression may be resolved during the interepisode period (22) (23) (24) .
In partial support of the second hypothesis, a negative relationship was observed between IL-6 and TST, which suggests that as TST decreased, IL-6 levels increased. However, only small effect sizes were observed between sTNF-R2 and TST. Results for IL-6 are consistent with those of Goldstein et al. (14) , as well as empirical research that demonstrates a link between short TST and inflammation (34, 55, 56) . This study also provides preliminary support for a theoretical article that hypothesized that IL-6 is related to sleep disturbance in BD (47) . To the best of our knowledge, this is the first study to provide evidence for this hypothesized relationship.
Small effect sizes were observed between TWT and proinflammatory cytokines. This finding is surprising given that other studies suggest that sleep disturbance is positively correlated with an inflammatory response (34, 38, 44) . Given the small sample size, small effect sizes, and the cross-sectional nature of the data, it is not possible to make definite conclusions about these results. One possibility that will need to be tested in future, fully powered studies is if the relationship between proinflammatory cytokines and sleep disturbance in BD is better captured by a measure of sleep duration (e.g., TST) or a measure of nocturnal wakefulness (e.g., TWT).
The third aim was to test whether CBTI-BP can affect proinflammatory cytokines in patients with interepisode bipolar I disorder and insomnia. These findings provide preliminary evidence that CBTI-BP may reduce IL-6 in patients with interepisode bipolar I disorder and insomnia. The change in IL-6 from pretreatment to posttreatment for CBTI-BP compared with PE was associated with a large effect size decrease. An inspection of the mean values indicated that patients who received CBTI-BP had lower IL-6 from pretreatment to posttreatment compared with patients who received PE. The group difference effect size was large, although the difference did not reach statistical significance. Results for sTNF-R2 were in the same direction as IL-6, but with small effect sizes. Taken together, a nonpharmacological intervention that improves sleep (e.g., CBTI-BP) may be a promising intervention to target proinflammatory cytokines in BD.
The within-group change in proinflammatory cytokines is also notable. The small-medium effect size decrease in IL-6 in the CBTI-BP condition should be evaluated in comparison with the PE group, which was associated with a large effect size increase in IL-6. Similar results were observed with sTNF-R2, but with smaller effect sizes. It is possible that for participants in the PE condition, sleep disturbance, as well as other factors related to inflammation such as return to mood episode, were not addressed to the same degree as CBTI-BP. Indeed, CBTI-BP compared with PE was associated with reduced risk of mood episode relapse and improved sleep (48) . In a fully powered study, it will be important to determine what factors mediate changes in proinflammatory cytokines as a result of treatment.
Several limitations are important to consider. First, the interpretability and generalizability of these findings are limited by the small sample size. Second, this study included adults with both insomnia and BD. Although insomnia occurs in 50% of interepisode BD patients (3), findings from this sample may not generalize to all patients with BD. Third, because of recommendations for small sample sizes and risk of overfitting statistical models (68), we did not control for variables known to influence proinflammatory cytokines such as age, sex, socioeconomic status, race and ethnicity, or body mass index (70) . In a fully powered study, it may be informative to evaluate the influence of these factors. Fourth, 95.5% of participants were prescribed mood stabilizers. Although this may bias the results, we suggest that the present study is notable because effects were observed despite most participants taking medication known to reduce inflammation (71) . Last, sTNF-R2 was related to study variables with small effect sizes. Although there is evidence that sTNF-R2 is related to BD (16), it is possible that this elevation is characteristic of acute illness phase rather than the interepisode period. Future studies will be necessary to further define the role of sTNF-R2 with respect to sleep and mood during the interepisode period.
In sum, this study provides preliminary evidence that IL-6 may be related to mood symptoms and sleep duration in participants with interepisode bipolar I disorder and insomnia. Furthermore, targeting sleep disturbance with CBTI-BP may result in changes in IL-6. Although the results of this study are encouraging, replication and further investigation in larger samples are warranted. 
